Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180588 | SCV000233059 | benign | not specified | 2014-07-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000180588 | SCV000242170 | benign | not specified | 2013-06-13 | criteria provided, single submitter | clinical testing | The variant is found in EPILEPSY,MITONUC-MITOP,CHILD-EPI,INFANT-EPI panel(s). |
Prevention |
RCV000180588 | SCV000309130 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000466342 | SCV000556237 | benign | Progressive sclerosing poliodystrophy | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002314677 | SCV000848520 | benign | Inborn genetic diseases | 2016-08-12 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Wong Mito Lab, |
RCV000466342 | SCV000887272 | benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.1586-5del (NP_002684.1:p.=) [GRCH38: NC_000015.10:g.89326743del] variant in POLG gene is interpretated to be a Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BS1:The minor allele frequency of this allele is high for Mitochondrial DNA depletion syndrome 4A (Alpers type). BS2:Observation of the variant in controls is inconsistent with penetrance of Mitochondrial DNA depletion syndrome 4A (Alpers type). BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Benign. |
ARUP Laboratories, |
RCV001812160 | SCV001473061 | benign | not provided | 2023-10-20 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000180588 | SCV001476782 | benign | not specified | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847820 | SCV002105556 | likely benign | Hereditary spastic paraplegia | 2022-01-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002500523 | SCV002810143 | benign | Progressive sclerosing poliodystrophy; Mitochondrial DNA depletion syndrome 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Mitochondrial DNA depletion syndrome 4b | 2021-08-05 | criteria provided, single submitter | clinical testing |